Celgene $BMY
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS20
PHASE 3 / 2-310
RECRUITING8
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO53%
Delay Index: of 19 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.2 months). See all sponsors →
Open Celgene on the live radar map → 📅 $BMY readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| AG-120 NCT02677922 |
P1/2 | Active, not recruiting | Leukemia, Myeloid, Acute | 130 | 2018-08-02 (-4 mo) |
| COMMANDS NCT03682536 |
P3 | Active, not recruiting | Myelodysplastic Syndromes | 363 | 2023-03-31 (+24 mo) |
| CC-220 NCT02773030 |
P1/2 | Active, not recruiting | Multiple Myeloma | 466 | 2024-05-09 (+69 mo) |
| INDEPENDENCE NCT04717414 |
P3 | Active, not recruiting | Myeloproliferative Disorders; Myelofibrosis | 313 | 2025-05-26 (+5 mo) |
| KarMMa-9 NCT06045806 |
P3 | Active, not recruiting | Multiple Myeloma | 79 | 2025-08-11 (-67 mo) |
| GOLSEEK-2 NCT06425302 |
P2 | Active, not recruiting | Lymphoma, Follicular | 95 | 2026-06-19 (-5 mo) |
| CC-92480 NCT03989414 |
P1/2 | Active, not recruiting | Multiple Myeloma | 424 | 2026-11-30 (+52 mo) |
| SUCCESSOR-1 NCT05519085 |
P3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 810 | 2027-01-10 (+14 mo) |
| CC-99282 NCT03930953 |
P1/2 | Active, not recruiting | Lymphoma, Non-Hodgkin | 438 | 2027-04-07 (+35 mo) |
| MSS NCT06782490 |
P2 | Recruiting | Multiple Sclerosis Spasticity | 200 | 2027-05-26 (+9 mo) |
| Elranatamab NCT06988488 |
P1/2 | Recruiting | Multiple Myeloma | 62 | 2027-05-31 |
| GOLSEEK-1 NCT06356129 |
P3 | Active, not recruiting | Large B-cell Lymphoma | 850 | 2027-08-09 (-12 mo) |
| rechARge NCT06764485 |
P3 | Active, not recruiting | Metastatic Castration-resistant Prostate Cancer | 960 | 2027-09-12 |
| EXCALIBER-RRMM NCT04975997 |
P3 | Active, not recruiting | Multiple Myeloma | 939 | 2027-11-16 (+42 mo) |
| BMS-986368 NCT06808984 |
P2 | Recruiting | Agitation; Alzheimer Disease | 120 | 2027-11-26 (+8 mo) |
| ACE-536 NCT04143724 |
P2 | Recruiting | Beta-Thalassemia | 99 | 2028-01-31 (+74 mo) |
| Golcadomide NCT06911502 |
P3 | Recruiting | Follicular Lymphoma | 400 | 2028-04-24 (-27 mo) |
| Luspatercept NCT04064060 |
P3 | Recruiting | Myelodysplastic Syndromes (MDS); Beta-thalassemia | 665 | 2028-05-12 (+4 mo) |
| TRANSCEND FL NCT04245839 |
P2 | Active, not recruiting | Lymphoma, Non-Hodgkin | 276 | 2031-09-30 (+107 mo) |
| Gene-modified (GM) T cell therapy NCT03435796 |
P2/3 | Recruiting | Neoplasms | 1541 | 2043-05-29 |